MX388748B - Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak. - Google Patents

Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.

Info

Publication number
MX388748B
MX388748B MX2019012950A MX2019012950A MX388748B MX 388748 B MX388748 B MX 388748B MX 2019012950 A MX2019012950 A MX 2019012950A MX 2019012950 A MX2019012950 A MX 2019012950A MX 388748 B MX388748 B MX 388748B
Authority
MX
Mexico
Prior art keywords
treatment methods
inhibitor compound
jak inhibitor
compound
methods
Prior art date
Application number
MX2019012950A
Other languages
English (en)
Other versions
MX2019012950A (es
Inventor
Glenn D Crater
Hao Zhang
Melanie A Kleinschek
Venkat R Thalladi
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2019012950A publication Critical patent/MX2019012950A/es
Publication of MX388748B publication Critical patent/MX388748B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se relaciona con métodos para tratar enfermedades oculares y determinadas enfermedades respiratorias mediante el uso del compuesto 5-etil-2-fluoro-4-(3-(5-(1-metilpiperidin-4-il)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-il)-1H-indazol-6-il)fenol (ver fórmula) o una sal farmacéuticamente aceptable del mismo
MX2019012950A 2017-05-01 2018-04-30 Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak. MX388748B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492568P 2017-05-01 2017-05-01
PCT/US2018/030140 WO2018204233A1 (en) 2017-05-01 2018-04-30 Methods of treatment using a jak inhibitor compound

Publications (2)

Publication Number Publication Date
MX2019012950A MX2019012950A (es) 2019-12-16
MX388748B true MX388748B (es) 2025-03-20

Family

ID=62165728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012950A MX388748B (es) 2017-05-01 2018-04-30 Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.

Country Status (17)

Country Link
US (4) US10406148B2 (es)
EP (1) EP3609498A1 (es)
JP (2) JP7153031B2 (es)
KR (1) KR102568333B1 (es)
CN (1) CN110573157B (es)
AU (1) AU2018261588A1 (es)
BR (1) BR112019022665A2 (es)
CA (1) CA3059785A1 (es)
CL (1) CL2019003126A1 (es)
MX (1) MX388748B (es)
MY (1) MY199353A (es)
PH (1) PH12019502345A1 (es)
RU (1) RU2764979C2 (es)
SG (1) SG11201909019SA (es)
TW (1) TW201900170A (es)
WO (1) WO2018204233A1 (es)
ZA (1) ZA201906817B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180073687A (ko) 2015-11-03 2018-07-02 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물
EA037748B1 (ru) 2017-03-09 2021-05-18 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Конденсированные имидазо-пиперидиновые ингибиторы jak
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
SG11201909019SA (en) * 2017-05-01 2019-10-30 Theravance Biopharma R&D Ip Llc Methods of treatment using a jak inhibitor compound
BR112021004087A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc processo para preparar inibidores de jak e seus intermediários
KR102826491B1 (ko) 2018-09-04 2025-06-27 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 디메틸 아미노 아제티딘 아마이드
US10836763B2 (en) 2018-09-04 2020-11-17 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as JAK inhibitors
JP2022506111A (ja) 2018-10-29 2022-01-17 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としての２－アザビシクロヘキサン化合物
IL285999B2 (en) 2019-03-05 2026-01-01 Incyte Corp JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction
WO2020251926A1 (en) * 2019-06-10 2020-12-17 Jenivision Inc. Methods and formulations for treating vision disorders
KR20220044487A (ko) 2019-06-17 2022-04-08 바이오마크 파마슈티칼스 리미티드 펩티드 및 포도막염의 치료에 있어서의 그의 사용 방법
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
EP3944859A1 (en) * 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
CN111973599A (zh) * 2020-08-07 2020-11-24 杭州邦顺制药有限公司 用于眼部疾病治疗的化合物
WO2022204473A1 (en) * 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound
TW202317550A (zh) 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
CN116785290B (zh) * 2023-02-01 2024-02-13 银谷制药有限责任公司 苯环喹溴铵及其异构体在制备眼用制剂中的应用
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024323272A1 (en) * 2023-08-11 2026-02-26 Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd. Jak inhibitor compound and use thereof
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
CN120305264B (zh) * 2025-06-16 2025-09-19 南昌大学第二附属医院 去泛素化酶otub1抑制剂的用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8193197B2 (en) 2006-10-19 2012-06-05 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
RU2560153C2 (ru) 2008-06-20 2015-08-20 Дженентек, Инк. Триазолпиридиновые соединения, ингибирующие jak, и способы
US20110184013A1 (en) * 2008-10-01 2011-07-28 Shelley Allen Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
KR101740076B1 (ko) * 2009-07-28 2017-06-08 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
US8450340B2 (en) 2009-12-21 2013-05-28 Samumed, Llc 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
EA024026B1 (ru) 2010-11-25 2016-08-31 Рациофарм Гмбх Новые соли и полиморфные формы афатиниба
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
CA2926361A1 (en) * 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
WO2015083028A1 (en) 2013-12-05 2015-06-11 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
WO2015168461A2 (en) 2014-04-30 2015-11-05 Agilent Technologies, Inc. Phosphorous protecting groups and methods of preparation and use thereof
EP3143021B1 (en) 2014-05-14 2019-06-12 Pfizer Inc Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
KR20180073687A (ko) 2015-11-03 2018-07-02 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물
ES2840650T3 (es) 2015-11-03 2021-07-07 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus
EP3371184A1 (en) 2015-11-03 2018-09-12 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EA037748B1 (ru) 2017-03-09 2021-05-18 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Конденсированные имидазо-пиперидиновые ингибиторы jak
SG11201909019SA (en) 2017-05-01 2019-10-30 Theravance Biopharma R&D Ip Llc Methods of treatment using a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
MY200348A (en) 2017-05-01 2023-12-21 Theravance Biopharma R&D Ip Llc Crystalline forms of a jak inhibitor compound

Also Published As

Publication number Publication date
US20220008403A1 (en) 2022-01-13
RU2019138463A (ru) 2021-06-02
JP2020518579A (ja) 2020-06-25
WO2018204233A1 (en) 2018-11-08
US20200121669A1 (en) 2020-04-23
EP3609498A1 (en) 2020-02-19
PH12019502345A1 (en) 2020-12-07
BR112019022665A2 (pt) 2020-05-19
KR102568333B1 (ko) 2023-08-18
MX2019012950A (es) 2019-12-16
US10406148B2 (en) 2019-09-10
US11786517B2 (en) 2023-10-17
US10548886B2 (en) 2020-02-04
NZ758109A (en) 2021-09-24
JP2022120147A (ja) 2022-08-17
US20190350916A1 (en) 2019-11-21
CA3059785A1 (en) 2018-11-08
CN110573157B (zh) 2023-04-04
TW201900170A (zh) 2019-01-01
CN110573157A (zh) 2019-12-13
SG11201909019SA (en) 2019-10-30
US11160800B2 (en) 2021-11-02
KR20190140062A (ko) 2019-12-18
JP7153031B2 (ja) 2022-10-13
AU2018261588A1 (en) 2019-10-31
MY199353A (en) 2023-10-24
ZA201906817B (en) 2021-10-27
RU2019138463A3 (es) 2021-08-03
CL2019003126A1 (es) 2020-01-24
RU2764979C2 (ru) 2022-01-24
US20180311226A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
MX388748B (es) Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
DOP2019000201A (es) Compuestos inhibidores del vih
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
NI202000092A (es) Compuestos
EA202193015A1 (ru) Ингибиторы cdk
MX2018004643A (es) Compuestos de benzolactama como inhibidores de la proteina cinasa.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
PH12019502425A1 (en) Crystalline forms of a jak inhibitor compound
CO2019004034A2 (es) Compuesto de piridina
ECSP20035590A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
UA118149C2 (uk) Інгібітор jak
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
AR103680A1 (es) Inhibidores selectivos de bace1
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
DOP2018000134A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
MX2017006110A (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
MX2019010108A (es) Derivados de azetidina.
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
AR099416A1 (es) Terapia combinada para la hipertensión resistente
MX2022000729A (es) Terapia de combinacion para el tratamiento del cancer.